Joseph Larosa

Executive VP, General Counsel & Secretary, Regeneron

Search every verified Joseph Larosa interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. At Regeneron Pharmaceuticals' 2025 annual shareholder meeting, held virtually on June 12, 2025, Joseph Larosa, serving as Executive Vice President, General Counsel, and Secretary, handled procedural and governance duties. He introduced the meeting's agenda, noted that the proceedings were being recorded for the company's investor relations website, and confirmed the use of the notice and access method for distributing proxy materials. He also reported the preliminary voting results, stating that all four Class I director nominees were elected by a majority of votes cast and that shareholders ratified the appointment of PricewaterhouseCoopers as the company's independent auditor. Larosa also managed the shareholder question-and-answer portion of the meeting, indicating when no further questions were presented and helping to conclude the proceedings. His remarks were limited to administrative and corporate governance matters, with no substantive commentary on business strategy or pipeline developments.